Kenvue Aktie News

Taking paracetamol, known as Tylenol in the U.S., during pregnancy is safe, a group of European researchers have said, after compiling data in response to U.S. President Donald Trump's claims of a link to autism last year.

Institutional Shareholder Services on ​Friday recommended that ‌shareholders approve plans by Kleenex maker Kimberly-Clark ‌to buy Tylenol maker ​Kenvue, saying a tie-up ‍could improve financial metrics.

Paying dividends is a priority for both companies. Procter & Gamble has paid dividends for 135 years.

NEW YORK and NEW ORLEANS, Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Insider buying can be one of the cleanest “follow-the-money” signals in the market. Over the past month or so, three names have stood out for $100 million-plus buying tied to prominent funds and well-known professional investors.

The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.

Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long-term expected annualized returns of at least 10%. Dividend growth for the Kings remains subdued at 5.81% for 2025, trailing the 2024 rate of 6.32%.

Dividend Kings remain largely overvalued, but six—including MO, UVV, HRL, KVUE, CDUAF, and UBSI—are now fairly priced with yields (from $1k invested) exceeding share prices. Analyst forecasts project net gains of 19.89% to 93.08% for select high-yield Dividend Kings by December 2026, with an average net gain of 34.89%. Only three Dividend Kings—MO, KVUE, UBSI—currently meet both the 'safer' div...